Biologic modulation of ionizing radiation by Toll-like receptors agonists: Towards an increase in the therapeutic index of radiotherapy?;Modulation biologique des radiations ionisantes par les agonistes des Toll-like receptors: Vers une amélioration de l'index thérapeutique de la radiothérapie?

Bulletin du Cancer

Volumn 99, Issue 5, 2012, Pages 545-550

  Riou, Olivier ^a,b   Azria, David ^a,b   Larbouret, Christel ^b   Robert, Bruno ^b  

^a CENTRE VAL D AURELLE   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

Agonists; Flagellin; Radiosensitivity modulation; Radiotherapy; Therapeutic index; Toll like receptors

Indexed keywords

FLAGELLIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST;

IMMUNOLOGY; IONIZING RADIATION; ONCOLOGY; RADIOSENSITIVITY; RADIOTHERAPY; REVIEW;

EID: 84861429233     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1578     Document Type: Article

References (36)

1. Rakoff-Nahoum S, Medzhitov R. Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry Moscow 2008; 73 : 555-61. (Pubitemid 351775078)
2. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9 : 57-63.
3. Roses RE, Xu M, Koski GK, Czerniecki BJ. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 2008; 27 : 200-7.
4. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine tuners of Toll-like receptor signalling. Nat Rev Immunol 2011; 11 : 163-75.
5. Quinn SR, O'Neill LA. A trio of microRNAs that control Toll-like receptor signalling. Int Immunol 2011; 23 : 421-5.
6. Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 2009; 87 : 125-38.
7. Demaria S, Bhardwaj N, Mcbride W, Formenti S. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63 : 655-66. (Pubitemid 41400049)
8. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009; 10 : 718-26.
9. Tesniere A, Apetoh L, Ghiringhelli F, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20 : 504-11.
10. Tallant T, Deb A, Kar N, Lupica J, de Veer MJ, DiDonato JA. Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells. BMC Microbiol 2004; 4 : 33.
11. Nempont C, Cayet D, Rumbo M, Bompard C, Villeret V, Sirard JC. Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol 2008; 181 : 2036-43.
12. Liu F, Yang J, Zhang Y, et al. Recombinant flagellins with partial deletions of the hypervariable domain lose antigenicity but not mucosal adjuvancy. Biochem Biophys Res Commun 2010; 392 : 582-7.
13. Vijay-Kumar M, Aitken JD, Sanders CJ, et al. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol 2008; 180 : 8280-5.
14. Rumbo M, Nempont C, Kraehenbuhl JP, Sirard JC. Mucosal interplay among commensal and pathogenic bacteria: lessons from flagellin and Toll-like receptor 5. FEBS Lett 2006; 580 : 2976-84. (Pubitemid 44250904)
15. Rydberg C, Månsson A, Uddman R, Riesbeck K, Cardell LO. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunology 2009; 128 : e600-611.
16. Gao N, Kumar A, Jyot J, Yu FS. Flagellin-induced corneal anti-microbial peptide production and wound repair involve a novel NF-kappaB-independent and EGFR-dependent pathway. PLoS ONE 2010; 5 : e9351.
17. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol 2009; 296 : H1-12.
18. Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008; 135 : 518-28.
19. Sfondrini L, Rossini A, Besusso D, et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006; 176 : 6624-30. (Pubitemid 43787845)
20. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008; 320 : 226-30. (Pubitemid 351521417)
21. Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003; 9 : 2693-700. (Pubitemid 36842115)
22. Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002; 169 : 3892-9.
23. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hämmerling GJ. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001; 167 : 5247-53. (Pubitemid 33009762)
24. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6 : 88-95. (Pubitemid 38898835)
25. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003; 9 : 3105-14. (Pubitemid 36993273)
26. Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol 2006; 80 : 192-8. (Pubitemid 44314019)
27. Milas L, Mason KA, Ariga H, et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 2004; 64 : 5074-7. (Pubitemid 39006521)
28. Mason KA, Ariga H, Neal R, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005; 11 : 361-9. (Pubitemid 40075816)
29. Leonard JP, Link BK, Emmanouilides C, et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007; 13 : 6168-74. (Pubitemid 350075077)
30. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117 : 1184-94. (Pubitemid 46718403)
31. Taylor PA, Ehrhardt MJ, Lees CJ, et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood 2008; 112 : 3508-16.
32. Fourcade J, Kudela P, Andrade Filho PA, et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008; 31 : 781-91.
33. Paun A, Fox J, Balloy V, Chignard M, Qureshi ST, Haston CK. Combined TLR2 and TLR4 deficiency increases radiation-induced pulmonary fibrosis in mice. Int J Radiat Oncol Biol Phys 2010; 77 : 1198-205.
34. Nilsson K, Henriksson R, Hellström S, Tengblad A, Bjermer L. Hyaluronan reflects the pre-fibrotic inflammation in irradiated rat lung: concomitant analysis of parenchymal tissues and bronchoalveolar lavage. Int J Radiat Biol 1990; 58 : 519-30. (Pubitemid 20281662)
35. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296 : 155-8. (Pubitemid 34280077)
36. Rosenbaum D, Peric S, Holecek M, Ward HE. Hyaluronan in radiation-induced lung disease in the rat. Radiat Res 1997; 147 : 585-91. (Pubitemid 27204095)